Skip to main content

Autolus Therapeutics plc

corporate_fare Company Profile

Autolus Therapeutics plc

AUTL·NASDAQ·Life Sciences·CIK 0001730463

We are an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering T cell therapies for cancer and autoimmune diseases. We use proprietary T cell programming technologies to engineer targeted T cell therapies designed to recognize and eliminate target cells. Our key product is AUCATZYL (obecabtagene autoleucel, also known as obe-cel), a B-lymphocyte antigen CD19 (CD19) chimeric antigen receptor (CAR) T cell therapy. AUCATZYL is designed with a fast target binding off-rate to minimize excessive activation of programmed T cells. In November 2024, the United States Food and Drug Administration (FDA) approved AUCATZYL for adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). The commercial launch and first sale in the United States occurred in January 2025. The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) granted AUCATZYL conditional marketing authorization in April 2025. In November 2025, the National Institute for Health and Care Excellence (NICE) recommended AUCATZYL for use in the National Health Service (NHS) in England and Wales for adult patients (age 26 and older) with r/r B-ALL. We launched AUCATZYL in the United Kingdom in January 2026, where it is available through routine NHS commissioning. In July 2025, the European Commission (EC) granted marketing authorization for AUCATZYL for adult patients (age 26 and older) with r/r B-ALL. Evaluation of pricing and market entry in certain European Union (EU) countries is ongoing, but launch in the EU is currently on hold, and we do not anticipate any EU sales of AUCATZYL in 2026.

Autolus Therapeutics plc (NASDAQ:AUTL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for AUTL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for AUTL spans 10-Q, 8-K, S-3, 10-K.

Recent high-impact activity:

  • Autolus Q3 10-Q: Revenue Doubles to $41.2M, Net Loss Narrows to $55.1M
  • AUCATZYL Revenue Doubles to $41.2M; Full-Year Guidance Raised Above $150M
  • Autolus' Obe-cel Wins FDA RMAT Designation for Lupus, Accelerating Path to Market
  • Autolus Therapeutics Removes Going Concern Doubt, Reports Strong Q2 Revenue Growth & Operational Efficiency
  • Autolus Q2 Revenue Surges 119% to $45.7M; 2026 Guidance Raised to $140–$150M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$75.39M
Net Income
-$287.53M
Diluted EPS
-$1.08
Op. Cash Flow
-$283.57M
Free Cash Flow
-$302.61M
Gross Profit
-$20.98M
Operating Income
-$270.54M
Cash & Equivalents
$104.13M
Debt / Equity
0.00×
Net Margin
-381.4%
Shares Outstanding
266.14M sh
Source: 10-K · filed 2026-03-27 · accession 0001730463-26-000038

Short Interest & Short Volume

4.73 days to cover

FINRA reported short interest of 8,628,641 shares in AUTL as of the October 30, 2026 settlement, a 4.8% decrease from the prior period — about 4.7 days to cover at its recent average daily volume. On November 20, 2026, 41.7% of AUTL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,628,641 shares as of October 30, 2026
Change vs prior period▼ 4.8%
Days to cover4.73 at avg daily volume of 1,825,559
Daily short volume (FINRA facilities)41.7% of 2,078,897 shares on November 20, 2026
5-day average short volume50.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for AUTL, detected from its recent SEC filings.

1 shelf registration

Resale Registration for Warrant Shares · No Proceeds to Company

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$0.92 +1.40% today
52-week range · as of 2026-11-10 $0.92 – $2.58
Market cap
$241.65M
Volume
3.9M (1.5× avg)
3-mo avg 2.6M
Live data · 2026-11-22 11:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AUTL - Latest Insights

AUTL
Nov 10, 2026, 4:47 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.32
Real-time Price: $0.920 info
Change: -$0.400 (-30%) info
Market Cap: $241.651M info
AUTL
Nov 10, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.36
Real-time Price: $0.920 info
Change: -$0.4379 (-32%) info
Market Cap: $241.651M info
AUTL
Sep 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.15
Real-time Price: $0.920 info
Change: -$1.23 (-57%) info
Market Cap: $241.651M info
AUTL
Aug 11, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.31
Real-time Price: $0.920 info
Change: -$1.39 (-60%) info
Market Cap: $241.651M info
AUTL
Aug 11, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.09
Real-time Price: $0.920 info
Change: -$1.17 (-56%) info
Market Cap: $241.651M info
AUTL
Aug 03, 2026, 9:17 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.67
Real-time Price: $0.920 info
Change: -$0.750 (-45%) info
Market Cap: $241.651M info
AUTL
Aug 03, 2026, 8:11 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.61
Real-time Price: $0.920 info
Change: -$0.685 (-43%) info
Market Cap: $241.651M info
AUTL
Aug 03, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.52
Real-time Price: $0.920 info
Change: -$0.600 (-39%) info
Market Cap: $241.651M info
AUTL
Jun 09, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.46
Real-time Price: $0.920 info
Change: -$0.540 (-37%) info
Market Cap: $241.651M info
AUTL
May 14, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.59
Real-time Price: $0.920 info
Change: -$0.670 (-42%) info
Market Cap: $241.651M info
AUTL
May 14, 2026, 7:53 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.63
Real-time Price: $0.920 info
Change: -$0.710 (-44%) info
Market Cap: $241.651M info
AUTL
May 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.70
Real-time Price: $0.920 info
Change: -$0.780 (-46%) info
Market Cap: $241.651M info
AUTL
Apr 29, 2026, 5:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.39
Real-time Price: $0.920 info
Change: -$0.470 (-34%) info
Market Cap: $241.651M info
AUTL
Apr 29, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.39
Real-time Price: $0.920 info
Change: -$0.470 (-34%) info
Market Cap: $241.651M info
AUTL
Apr 16, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $0.920 info
Change: -$0.690 (-43%) info
Market Cap: $241.651M info
AUTL
Apr 10, 2026, 5:56 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.49
Real-time Price: $0.920 info
Change: -$0.5699 (-38%) info
Market Cap: $241.651M info
AUTL
Apr 10, 2026, 5:52 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $1.49
Real-time Price: $0.920 info
Change: -$0.5699 (-38%) info
Market Cap: $241.651M info
AUTL
Apr 08, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $0.920 info
Change: -$0.5792 (-39%) info
Market Cap: $241.651M info
AUTL
Mar 27, 2026, 4:39 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.21
Real-time Price: $0.920 info
Change: -$0.290 (-24%) info
Market Cap: $241.651M info
AUTL
Mar 27, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.25
Real-time Price: $0.920 info
Change: -$0.330 (-26%) info
Market Cap: $241.651M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets